profit from every £100 of sales.
£0£100
Uniphar
£3.61+0.00% today
+8.7% in 1 year
1-year low £2.991-year high £4.22
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay £22.54 for every £1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Uniphar sold, what it kept, and what it did with the cash.
Sales went from €2.07 billion in 2022 to €3.07 billion in 2025, with €51.1 million of profit last year.
SalesProfit
Uniphar handed back 88% of the cash it generated last year.
Buybacks €35M
Free cash flow 2025€46M
Bought back its own shares€35M
Paid as dividends€5M
Cash vs. debt€184M vs. €513M
Uniphar vs. similar companies
Uniphar grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from £100 of sales | Sales growth a year | Price per £1 of profit |
|---|---|---|---|
| Uniphar | 22.5× · Fair price | ||
 McKesson | 26.2× · Fair price | ||
 Cencora | 43.0× · Expensive | ||
 Cardinal Health | 41.1× · Expensive | ||
 Sigma Healthcare | 63.4× · Very expensive |
AI analysis
An AI analyst reads Uniphar's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,071 | 2,553 | 2,770 | 3,075 | |
| 307 | 390 | 428 | 458 | |
| 70 | 78 | 85 | 91 | |
| 95 | 113 | 137 | 120 | |
| 46 | 45 | 64 | 51 | |
| 0.17 | 0.16 | 0.24 | – | |
| 14.8% | 15.3% | 15.4% | 14.9% | |
| 3.4% | 3.0% | 3.1% | 3.0% | |
| 2.2% | 1.8% | 2.3% | 1.7% |
Balance sheet
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,111 | 1,290 | 1,416 | 1,732 |
| Cash | 104 | 86 | 103 | 184 |
| Total debt | 315 | 382 | 406 | 513 |
| Total liabilities | 821 | 956 | 1,014 | 1,327 |
| 290 | 333 | 402 | 405 | |
| 273 | 273 | 273 | – | |
| 8.2% | 8.1% | 9.4% | 6.9% | |
| 15.7% | 13.5% | 16.0% | 12.6% |
Cash flow
| In millions of EUR | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 83 | 53 | 124 | 108 | |
| 20 | 32 | 102 | 63 | |
| 63 | 21 | 22 | 46 | |
| Dividends paid | 5 | 5 | 5 | 5 |
| – | – | 0 | 35 | |
| 1 | 3 | 3 | 4 |
Valuation
- 22.5×
- –
- –
- 2.7×
- 0.4×
- 25.2×
- 12.4×
- 4.0%
- 4.4%
- 0.4%
Profitability
- 14.9%
- 3.0%
- 1.7%
- –
- 6.9%
- 8.2%
- –
- –
- –
- –
Growth
- +14.1%
- –
- –
- –
- +0.4%
Financial health
- 2.7×
- 1.27
- –
- 4.0×
- 0.99
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 44%of 958
Bottom 32%of 888
Top 42%of 600
Top 40%of 889
Top 29%of 987
0.4%of the share price, paid each year
On $1,000 invested$4a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
9.9% of its profit
Room to growStretchedMore than it earns: 11.1%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
41No pass
Benjamin Graham
45No pass
Philip Fisher
40No pass
Peter Lynch
48No pass
Joel Greenblatt
27No pass
Charlie Munger
23No pass
Terry Smith
29No pass
Questions about Uniphar
Is Uniphar a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Uniphar AI analysis
What does Uniphar do?
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It is in Medical Distribution, based in Dublin, Ireland, with 3,500 employees.
Does Uniphar pay a dividend?
Yes. At today's price the dividend is 0.4% a year, about 10% of its yearly profit. In 2025 it paid out £5.08 million in dividends.
Is Uniphar stock halal?
No. Uniphar does not pass our halal screen: its debt is 45% of its market value, at or above the 33% limit. How we check
How has Uniphar stock done over the past year?
Up 8.7% over the past twelve months, to £3.61. It traded between £2.99 and £4.22 and is 14.5% below its high.
Who are Uniphar's competitors?
The largest listed companies in the same industry are McKesson, Cencora, Cardinal Health and Sigma Healthcare. The peers table on this page compares their profit, growth and price with Uniphar's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.